Sabirnetug (ACU193) - Intravenous (IV)
Early Alzheimer's Disease
Key Facts
Indication
Early Alzheimer's Disease
Phase
Phase 2
Status
Active - ALTITUDE-AD trial ongoing
Company
About Acumen Pharmaceuticals
Acumen Pharmaceuticals leverages decades of research on amyloid-beta oligomers to pioneer next-generation Alzheimer's treatments. The company's lead asset, sabirnetug, is the first immunotherapy candidate to enter the clinic specifically targeting toxic soluble AβOs, aiming for improved efficacy and safety over plaque-targeting antibodies. With positive Phase 1 results reported and a Phase 2 trial underway, Acumen is positioned at a critical inflection point in the competitive Alzheimer's therapeutic landscape. The company is led by an experienced team of Alzheimer's drug development veterans and is backed by public market investors.
View full company profileTherapeutic Areas
Other Early Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Lecanemab (Leqembi®) | BioArctic AB | Approved |
| AL101 / GSK4527226 | Alector | Phase 2 |
| AL002 | Alector | Phase 2 |
| Sabirnetug (ACU193) - Subcutaneous (SC) | Acumen Pharmaceuticals | Phase 1 |
| Enhanced Brain Delivery (EBD™) [TfR-Brain transporter + AβO mAb] | Acumen Pharmaceuticals | Preclinical |